Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bile acid transporter modulation is a pharmacological strategy that targets key proteins responsible for the absorption, export, and overall regulation of bile acids in the enterohepatic circulation. Major transporters include NTCP (liver uptake), ASBT/IBAT (intestinal reuptake), BSEP (canalicular export from hepatocytes), and OSTα/β (facilitated diffusion across basolateral membranes). Modulation of these transporters is clinically valuable for the treatment of cholestatic pruritus, genetic cholestatic disorders, metabolic liver diseases, and has notable implications for drug safety as inhibition can lead to cholestasis and liver injury. Specific transporter inhibitors are approved or in development, and transporter function is central to bile acid-related physiology and pathophysiology.
Inhibition of bile acid uptake (ASBT/IBAT, NTCP); Restoration or enhancement of bile acid export (BSEP activators—not commercially available); Indirect modulation by FXR agonists; Competitive inhibition of transporter function (reducing bile acid pool, altering composition, increasing fecal excretion)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bile acids transporter modulation.